title: Polymorphism in the interleukin-17A promoter contributes to gastric cancer.
abstract: OBJECTIVE
  To evaluate the contribution of the G-197A polymorphism in the interleukin-17 (IL-17) promoter region to gastric cancer risk in an Iranian population.
  
  
  METHODS
  We performed a case control study using samples from 161 individuals with gastric cancer and 171 healthy controls. For each individual, the G-197A genotype was determined by restriction fragment length polymorphism analysis of polymerase chain reaction-amplified fragments. Statistical analyses were performed to determine whether any demographic or behavioral factors, infection with Helicobacter pylori (H. pylori), or a particular G-197A genotype was associated with gastric cancer risk.
  
  
  RESULTS
  We found that the G-197A genotype was significantly associated with increased gastric cancer risk (P = 0.001). Patients who were homozygous (AA) at position -197 were 2.9 times more likely to develop disease (95%CI: 1.56-5.4; P = 0.001). Furthermore, logistic regression analysis revealed that the presence of a single A allele increased the risk of gastric cancer up to 1.7-fold (95%CI: 1.26-2.369; P = 0.001). This association was observed for early stage gastric adenocarcinomas only, and was not linked to H. pylori infection.
  
  
  CONCLUSIONS
  These results suggest that carrying one or more G-197A polymorphisms at position -197 in the IL-17 promoter region significantly increases gastric cancer risk in this patient population.
authors.affiliation: Alireza Rafiei, Abuzar Ghorbani, Abulghasem Ajami, Touraj Farzmandfar, Maedeh Darzyani Azizi, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari 48175-1665, Iran.
authors.forename: Alireza
authors.initials: A
authors.lastname: Rafiei
authors.forename: Vahid
authors.initials: V
authors.lastname: Hosseini
authors.forename: Ghasem
authors.initials: G
authors.lastname: Janbabai
authors.forename: Abuzar
authors.initials: A
authors.lastname: Ghorbani
authors.forename: Abulghasem
authors.initials: A
authors.lastname: Ajami
authors.forename: Touraj
authors.initials: T
authors.lastname: Farzmandfar
authors.forename: Maedeh Darzyani
authors.initials: MD
authors.lastname: Azizi
authors.forename: Jeremy J
authors.initials: JJ
authors.lastname: Gilbreath
authors.forename: D Scott
authors.initials: DS
authors.lastname: Merrell
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000235:genetics*; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D020381:Interleukin-17 / Q000235:genetics*; D007492:Iran / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D013274:Stomach Neoplasms / Q000453:epidemiology / Q000235:genetics*
chemical_list: C508717:IL17A protein, human; D020381:Interleukin-17
keywords: Cancer; Gastric cancer; Helicobacter pylori; Interleukin-17A
references.citation: Intern Emerg Med. 2014 Apr;9(3):303-9
references.pmid: 23054412
references.citation: Gastroenterology. 2007 Sep;133(3):926-36
references.pmid: 17854597
references.citation: Int J Epidemiol. 1996 Jun;25(3):494-504
references.pmid: 8671549
references.citation: Cancer Sci. 2005 Jan;96(1):1-6
references.pmid: 15649247
references.citation: Cancer Causes Control. 2011 May;22(5):725-36
references.pmid: 21347819
references.citation: J Immunol. 1995 Dec 15;155(12):5483-6
references.pmid: 7499828
references.citation: Biochem Biophys Res Commun. 2008 Sep 26;374(3):533-7
references.pmid: 18655770
references.citation: Cytokine Growth Factor Rev. 2003 Apr;14(2):155-74
references.pmid: 12651226
references.citation: Carcinogenesis. 2005 Mar;26(3):631-6
references.pmid: 15579481
references.citation: Rheumatology (Oxford). 2009 Apr;48(4):367-70
references.pmid: 19208686
references.citation: Gut Pathog. 2009 Jun 22;1(1):12
references.pmid: 19545429
references.citation: Annu Rev Immunol. 2009;27:485-517
references.pmid: 19132915
references.citation: Int J Cancer. 2009 Oct 15;125(8):1953-60
references.pmid: 19569234
references.citation: J Clin Immunol. 2008 Jan;28(1):44-9
references.pmid: 17828618
references.citation: Diabetes Res Clin Pract. 2010 Jun;88(3):222-6
references.pmid: 20392505
references.citation: J Biol Chem. 2004 Dec 10;279(50):52762-71
references.pmid: 15459204
references.citation: Acta Pathol Microbiol Scand. 1965;64:31-49
references.pmid: 14320675
references.citation: Gastric Cancer. 2007;10(2):75-83
references.pmid: 17577615
references.citation: J Biol Chem. 1995 Jul 28;270(30):17771-7
references.pmid: 7629077
references.citation: Nucleic Acids Res. 1988 Feb 11;16(3):1215
references.pmid: 3344216
references.citation: Clin Cancer Res. 1999 Jun;5(6):1411-5
references.pmid: 10389926
references.citation: J Clin Invest. 2007 Jan;117(1):60-9
references.pmid: 17200707
references.citation: Gut. 2003 Jan;52(1):65-70
references.pmid: 12477762
references.citation: Int J Cancer. 2010 Jul 1;127(1):86-92
references.pmid: 19904747
references.citation: Hum Immunol. 2009 Jul;70(7):547-51
references.pmid: 19414056
references.citation: BMC Microbiol. 2009 Dec 02;9:248
references.pmid: 19954539
references.citation: Nature. 2000 Mar 23;404(6776):398-402
references.pmid: 10746728
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Clin Chim Acta. 2011 Jan 30;412(3-4):327-31
references.pmid: 21062626
references.citation: J Clin Pathol. 2004 Jan;57(1):37-42
references.pmid: 14693833
references.citation: Bone Marrow Transplant. 2011 Nov;46(11):1455-63
references.pmid: 21217785
references.citation: Dig Dis Sci. 2008 Jan;53(1):27-33
references.pmid: 17492381